Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma priorities.
According to StatNews, AbbVie has ended its 11-year collaboration with Calico Labs, the Alphabet-backed biotech created to tackle aging and age-related disease. The move brings to a close one of the most high-profile alliances between big pharma and big tech; around 100 scientists and chemists are expected to be affected by layoffs following the dissolution of the joint research programs.
The partnership, formed in 2014, combined AbbVie’s drug development infrastructure with Calico’s deep-biology approach to aging and neurodegeneration. Despite multiple renewals and substantial investment – reportedly over a billion dollars in total – the collaboration delivered limited clinical success. Calico’s amyotrophic lateral sclerosis (ALS) candidate, fosigotifator, failed to meet its endpoints, and AbbVie is reportedly moving away from small-molecule discovery – the core of its work with Calico – toward biologics and advanced modalities that align more closely with its current portfolio.
Longevity.Technology: The end of AbbVie’s partnership with Calico is less a post-mortem than a milestone – a reminder that the biology of aging may be universal, but its translation into profitable pipelines is anything but. For all Calico’s resources and brainpower, the stubborn truth remains that geroscience moves at the pace of biology itself; mitochondria and senescent cells are not easily persuaded by capital injections. Yet there’s something instructive in this reset. The longevity sector is maturing – investors are asking sharper questions, companies are narrowing focus and hype is yielding to hard data. If the past decade was about proving aging could be targeted, the next may be about proving it can be commercialised. Failure, inconvenient though it is, often teaches faster than funding.
Perhaps AbbVie’s decision also signals a pragmatic retreat from the long game of fundamental aging science toward nearer-term returns; drug development timelines are long enough without adding the uncertainties of a still-nascent field. Calico’s lofty beginnings – fuelled by Alphabet’s conviction that aging could be decoded with enough data and determination – always carried a touch of Silicon Valley hubris, the assumption that biology would yield to computational willpower (although companies such as Insilico are beginning to demonstrate that AI-driven discovery can, with persistence, deliver tangible results). A decade on, AbbVie may simply have lost patience with promise unfulfilled. Still, this parting of the ways need not be read as an obituary for longevity biotech, but rather as a recalibration: the industry learning that extending healthspan demands not only scientific ingenuity, but strategic endurance – and perhaps a little less faith in moonshots.
Calico’s statement and future plans
A Calico spokesman told Fierce Biotech: “We’re deeply appreciative of our partnership with AbbVie, which has played an important role in shaping Calico’s clinical development capabilities. As we look ahead, we’ll continue advancing the development of many of these programs while expanding our internal development infrastructure to advance more programs independently, while also forming new collaborative partnerships to bring expertise and technologies to enhance our current capabilities.”
Calico, which emerged from Google’s “moonshot factory” in 2013 under the direction of Arthur Levinson and with backing from Larry Page, was conceived as a long-horizon enterprise: to understand the biology of aging and translate that knowledge into new therapeutics. Recent licensing of an IL-11 antibody program from China hints that the company is refining, not abandoning, its ambitions.
Industry reflections
Writing on LinkedIn, Insilico Medicine’s Alex Zhavoronkov described the news as “sad for the longevity industry”, noting that while Calico received extraordinary attention and investment, its output has lagged expectations. He suggested that Alphabet might have done better to merge Calico’s capabilities with Isomorphic Labs, applying AI-driven discovery directly to aging-related targets – a proposal that captures both the frustration and optimism rippling through the field.
After the honeymoon
AbbVie’s withdrawal may mark the end of one of longevity’s most visible alliances, but it also signals a new phase in which the field must balance vision with viability. As the industry shifts from grand declarations to grounded execution, the lessons of Calico and AbbVie will likely inform a more pragmatic generation of partnerships – ones that match scientific ambition with patient capital and clear translational routes. Aging, after all, remains undefeated; progress in the field will depend on endurance as much as inspiration.
